Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when DNTH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsDianthus wins FDA approval to remove lupus screening from claseprubart trials
Filed March 26, 2026 · Period ending March 26, 2026 · ~1 min read
Key Changes
-
high
FDA approved removal of anti-nuclear antibody (ANA) screening requirements for all claseprubart trials, eliminating a common reason for patient screen failures and streamlining enrollment.
Item 8.01 verify on EDGAR → -
high
FDA agreed to reclassify hypothetical lupus risk from systemic lupus to reversible drug-induced lupus and eliminate routine ANA testing during trials, reflecting accumulated safety data.
Item 8.01 verify on EDGAR → -
high
Company disclosed zero cases of systemic lupus or drug-induced lupus across all claseprubart programs to date, supporting the FDA's decision to relax safety monitoring requirements.
Item 8.01 verify on EDGAR → -
low
Updated corporate presentation posted to investor relations website, filed as Exhibit 99.1.
Item 9.01 verify on EDGAR →
Summary
Dianthus Therapeutics announced a significant regulatory win: the FDA approved three protocol changes across all ongoing and planned claseprubart trials. Most importantly, the agency agreed to remove anti-nuclear antibody screening as an enrollment criterion—a change that should accelerate patient recruitment by eliminating a common screen failure.
The FDA also eliminated routine ANA testing during trials and reclassified the theoretical lupus risk from systemic to drug-induced (a reversible condition). These changes matter because they reflect the FDA's confidence in claseprubart's safety profile after reviewing accumulated data showing zero lupus cases to date. Faster enrollment could accelerate trial timelines and reduce development costs.
For retail investors, this is a meaningful de-risking event that validates the drug's safety and improves the probability of timely clinical readouts. Watch for updates on enrollment rates in upcoming quarterly reports to see if the protocol changes translate into faster patient accrual.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
In March 2026, the Company received written feedback from FDA agreeing to all three of these proposals for all ongoing and planned future claseprubart trials.
The FDA approved three protocol changes for all claseprubart trials: removing anti-nuclear antibodies (ANAs) as screening criteria (which had been a common screen failure reason), eliminating routine ANA testing during trials, and reclassifying the hypothetical systemic lupus erythematosus risk to drug-induced lupus (a reversible side effect). These changes streamline patient enrollment and reflect accumulated safety data.
Added in current filing · verify on EDGAR →
Of note there have been no cases of either SLE or DIL to date in any claseprubart program.
The company disclosed that across all claseprubart programs to date, there have been zero cases of systemic lupus erythematosus or drug-induced lupus. This safety record supported the FDA's agreement to reclassify the hypothetical autoimmune risk and remove related screening requirements.
Event · Item 9.01 — Financial Statements and Exhibits
Dianthus Therapeutics filed an 8-K to furnish a corporate presentation dated March 2026.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1
Corporate Presentation of Dianthus Therapeutics, Inc., dated March 2026
The company furnished a corporate presentation dated March 2026 as Exhibit 99.1. This is a routine disclosure under Item 9.01, typically used to share investor materials such as conference presentations or business updates. Without access to the presentation content, the materiality and specific disclosures cannot be assessed.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify